REGN earnings call for the period ending December 31, 2019.
News & Analysis: Regeneron Pharmaceuticals
Two drugs drove its fourth-quarter sales growth, and the company expects to have an experimental treatment for 2019n-CoV coronavirus in a few months.
Here's how the biotech topped Wall Street estimates on both the top and bottom lines in Q4.
The eczema drug is already approved for patients 12 and older; this proposal would allow it to be prescribed to those as young as 6.
REGN earnings call for the period ending September 30, 2019.
As Eylea and Dupixent go, so goes Regeneron.
REGN earnings call for the period ending June 30, 2019.
Revenue and earnings beat Wall Street estimates thanks to solid growth for Eylea and Dupixent.
It can be tough to pick winners in the world of pharmaceutical development, but Alexion, Regeneron, and Ionis offer investors good chances of strong returns.
Here's how these biotech stocks became the biggest on the market -- and how their future prospects look.